NIH Mix and Match Study Suggests mRNA COVID Vaccines May Offer Stronger Boost Than J&J

Though not designed to facilitate inter-group comparisons, a preprint study of heterologous and homologous boosting with the three US available COVID-19 vaccines indicate Johnson and Johnson primary vaccines may get greater protection from an mRNA booster.

NIH National Institue of Allergy and Infectious Diseases building — FDA's vaccine advisors will hear a presentation on mixing and matching COVID-19 booster shots from NIAID on 15 October. • Source: Alamy

People who got a booster dose of an mRNA COVID-19 vaccine following primary vaccination with Johnson & Johnson’s adenovirus COVID-19 vaccine generated a stronger antibody response than J&J patients boosted with another one of the sponsor’s adenovirus shots, new data from the US National Institutes of Health shows, throwing a possible wrench in J&J’s ability to capitalize on US boosters.

The US Food and Drug Administration’s Vaccine and Related Biological Products Advisory Committee is expected to vote on 15 October...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

US FDA’s Elsa AI Platform Is Not Guiding Regulatory Decisions, Official Says

20 Jun 2025

• By Cathy Kelly

Tala Fakhouri said the agency’s use of the AI tool in the review process has generated lots of questions.

Branch Chief Vijay Kumar Named Acting Head Of US FDA’s Cell, Gene Therapy Office

20 Jun 2025

• By Derrick Gingery

Kumar takes over as acting director of the Center for Biologics Evaluation and Research’s Office of Therapeutic Products days after director Nicole Verdun was ousted.